Related Experiment Video
Updated: Apr 3, 2026

08:06
Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
Published on: November 27, 2019
9.7K
Energy restriction and potential energy restriction mimetics
Sibylle Nikolai1, Kathrin Pallauf1, Patricia Huebbe1
1Institute of Human Nutrition and Food Science,University of Kiel,Kiel,Germany.
Nutrition Research Reviews
|September 23, 2015
Summary
Energy restriction (ER) may extend lifespan and delay aging. While some substances mimic ER effects, their benefits and safety in humans are not yet proven.
Area of Science:
- Gerontology
- Nutritional Science
- Pharmacology
Background:
- Energy restriction (ER), or caloric restriction, is a proven method to increase lifespan in model organisms and may delay human aging.
- Understanding the molecular, metabolic, and hormonal effects of ER is crucial for developing anti-aging strategies.
Purpose of the Study:
- To review the scientific literature on energy restriction (ER) and its effects.
- To summarize criteria for classifying substances that mimic ER effects (ERM) without reducing caloric intake.
- To discuss potential ERMs, their molecular targets, and their efficacy and safety in higher organisms.
Main Methods:
- Literature review of scientific studies on energy restriction and its mimetics.
- Analysis of molecular, metabolic, and hormonal effects associated with ER.
- Evaluation of data on lifespan extension and safety of ERM candidates in model organisms and higher organisms.
Main Results:
- ER is the only nutritional intervention consistently shown to extend lifespan in model organisms.
- Several ERM candidates (e.g., metformin, resveratrol) show promise in model organisms but have controversial or missing data in higher organisms.
- Some ERMs have significant side effects (e.g., immunosuppression, lactic acidosis) or lack long-term safety data.
Conclusions:
- No current ERM can be recommended without limitations for human use due to inconsistent efficacy and safety concerns.
- Further research is needed to identify safe and effective ERMs for human longevity and aging delay.
- The development of safe ERMs remains a significant challenge in gerontology and nutritional science.
Keywords:
2DG 2-deoxy-d-glucoseAMPK AMP-activated protein kinaseER energy restrictionERM energy restriction mimeticFOXO forkhead box OGH growth hormoneIGF-1 insulin-like growth factor 1NIA United States National Institute on AgingNrf2 nuclear factor (erythroid-derived 2) like 2PGC1α PPAR γ coactivator 1-αROSRSV resveratrolSIRT sirtuinSOD superoxide dismutaseSPD spermidineT2DM type 2 diabetes mellitusUCP uncoupling proteinmTOR mammalian target of rapamycinmTORC1 mammalian target of rapamycin complex 1p-AMPK phosphorylated AMPKreactive oxygen speciesEnergy restrictionEnergy restriction mimeticsHealthy ageingLifespanLongevityRelated Concept Videos
Restriction Enzymes
39.2K
Restriction enzymes are bacterial enzymes used to cut DNA in a sequence-specific manner. To cleave DNA, they bind to specific palindromic sequences called restriction sites. Such palindromic DNA sequences or inverted repeats are commonly found in regions of functional significance, such as the origin of replication, gene operator sites, and regions containing transcription termination signals.
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
The host bacteria protect their own genomic DNA from these enzymes by methylating these sites. Some...
39.2K
Adrenergic Agonists: Direct-Acting Agents
3.1K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
3.1K
Spare Receptors
4.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.8K
Adrenergic Agonists: Indirect-Acting Agents
3.0K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K
Potential Energy
44.0K
The energy stored by a structure and location of matter in space is called potential energy. For instance, raising a kettlebell changes its spatial location and increases its potential energy. Similarly, a stretched rubber band contains potential energy which, under certain conditions, can be converted into other forms of energy, such as kinetic energy.
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
44.0K
Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K

